dctd-celltherapyconf (Agenda)

December 10th, 2020

NCI Welcome
James Doroshow, MD
Rose Aurigemma, PhD
Marc Ernstoff, MD

Choosing the Target: Specificity and Toxicity
Chair: Madhav Dhodapkar, MBBS (Emory University)

9:15am – 9:45am, Selecting and Validating Targets, Isolating High Affinity TCRs, and Engineering T Cells That Can Be Effective in Therapy, Philip Greenberg, MD (Fred Hutchinson Cancer Research Center)

9:45am – 10:15am, Development of Combinatorial Antigen Sensing T Cell Therapeutics for Solid Tumors, Kole Roybal, PhD (University of California, San Francisco)

10:15am – 10:45am, Targeting Solid Malignancies With “Public” Neoantigen-Specific T Cell Receptors, Christopher Klebanoff, MD (Memorial Sloan Kettering Cancer Center)

10:45am – 11:15am, Safety and Clinical Activity of Engineered TCR-T Cells for HPV-Associated Cancers, Christian Hinrichs, MD (National Cancer Institute)

Panel Discussion
Laronna Colbert, MD (Food and Drug Administration)
Madhav Dhodapkar, MBBS (Emory University)
Philip Greenberg, MD (Fred Hutchinson Cancer Research Center)
Christian Hinrichs, MD (National Cancer Institute)
Christopher Klebanoff, MD (Memorial Sloan Kettering Cancer Center)
Wendell Lim, PhD (University of California, San Francisco)
Kole Roybal, PhD (University of California, San Francisco)

Keynote Talk

Approaches to Augment Potency of CAR T Cell Therapies, Crystal Mackall, MD (Stanford University)

Break

Reaching the Target: Modulating the Tumor Microenvironment
Chair: Yvonne Chen, PhD (University of California, Los Angeles)

1:00pm – 1:30pm, Feast to Famine: Preparing Therapeutic T Cells for Intratumoral Function Through Metabolic Reprogramming, Greg Delgoffe, PhD (University of Pittsburgh)

1:30pm – 2:00pm, Armored CAR T Cells and Solid Tumor Malignancies, Renier Brentjens, MD, PhD (Memorial Sloan Kettering Cancer Center)

2:00pm – 2:30pm, Enhancing Cell Therapies by Overcoming TGFβ in the TME, Catherine Bollard, MD, MBChB (Children’s National Research Institute and George Washington University)

2:30pm – 3:00pm, Does It Make Sense to Add Immune Checkpoint Blockade to Adoptive Cell Transfer Therapies? Antoni Ribas, MD, PhD (University of California, Los Angeles)

Panel Discussion
Catherine Bollard, MD, MBChB (Children’s National Research Institute)
Renier Brentjens, MD, PhD (Memorial Sloan Kettering Cancer Center)
Yvonne Chen, PhD (University of California, Los Angeles)
Greg Delgoffe, PhD (University of Pittsburgh)
Michael Hudecek, MD (Universitätsklinikum Würzburg, Germany)
Antoni Ribas, MD, PhD (University of California, Los Angeles)
Cliona Rooney, PhD (Baylor College of Medicine)

Break

Immune Cell Fitness and Persistence
Chair: Alex Marson, MD, PhD (University of California, San Francisco)

4:00pm – 4:30pm, The Tug-o-War Between CAR T and Solid Tumors, Carl June, MD (University of Pennsylvania)

4:30pm – 5:00pm, Driving CAR T Cells into Solid Tumors Without Exhaust(ion), Stanley Riddell, MD (Fred Hutchinson Cancer Research Center)

5:00pm – 5:30pm, Decoding T Cell Dysfunction in Solid Tumors, Andrea Schietinger, PhD (Memorial Sloan Kettering Cancer Center)

5:30pm – 6:00pm, Decoding and Reprogramming T Cell Fitness with CRISPR, Alex Marson, MD, PhD (University of California, San Francisco)

Panel Discussion
Ananda Goldrath, PhD (University of California, San Diego)
Carl June, MD (University of Pennsylvania)
Wendell Lim, PhD (University of California, San Francisco)
Alex Marson, MD, PhD (University of California, San Francisco)
Stanley Riddell, MD (Fred Hutchinson Cancer Research Center)
Andrea Schietinger, PhD (Memorial Sloan Kettering Cancer Center)

December 11th, 2020

Day 1 Recap
Marc Ernstoff, MD (NCI)

Keynote Talk
Emerging Challenges and Strategies with CAR T Cells, Marcela Maus, MD, PhD (Harvard Medical School and Massachusetts General Hospital)

Alternative Approaches: Looking Beyond Traditional CAR-T Cells
Chair: Tonya Webb, PhD (University of Maryland)

9:45am – 10:15am, Cellular Therapy of Solid Epithelial Cancers Using Naturally Occurring or Genetically Modified Anti-Tumor T Cells, Steven Rosenberg, MD, PhD (National Cancer Institute)

10:15am – 10:45am, Looking Beyond Traditional CAR-T Cells: Unconventional T Cells, Stem Cell Engineering, and an Off-The-Shelf Cell Therapy, Lili Yang, PhD (University of California, Los Angeles)

10:45am – 11:15am, Dendritic Cells: Vaccines, Modulation of Tumor Microenvironment and Adoptive T Cell Therapies, Pawel Kalinski, MD, PhD (Roswell Park Comprehensive Cancer Center)

11:15am – 11:45am, Clinical and Immunologic Effects of Bispecific Antibody Targeted T Cells for Metastatic Breast and Pancreatic Cancer, Lawrence Lum, MD, DSC (University of Virginia)

Panel Discussion
Pawel Kalinski, MD, PhD (Roswell Park Comprehensive Cancer Center)
Dan Kaufman (University of California, San Diego)
Lawrence Lum, MD, DSC (University of Virginia)
Steven Rosenberg, MD, PhD (National Cancer Institute)
Tonya Webb, PhD (University of Maryland)
Lili Yang, PhD (University of California, Los Angeles)

Break

Cell Product Manufacturing and Characterization
Chair: Bruce Levine, PhD (University of Pennsylvania)

1:00pm – 1:30pm, The Role of Standards in Supporting Cell-Based Therapies & Genome Editing Technology, Samantha Maragh, PhD (National Institute of Standards and Technology)

1:30pm – 2:00pm, Design, Engineer, Validate, Build, Test: Manufacturing the Next Generation of Cell Therapies Targeting Solid Cancers, Bruce Levine, PhD (University of Pennsylvania)

2:00pm – 2:30pm, Manufacturing Matters: Population, Phenotype & Potency, Christine Brown, PhD (City of Hope)

2:30pm – 3:00pm, Considerations for Manufacturing an Allogeneic Cell Product, Barbra Sasu, PhD (Allogene Therapeutics)

Panel Discussion
Christine Brown, PhD (City of Hope)
Bruce Levine, PhD (University of Pennsylvania)
Samantha Maragh, PhD (National Institute of Standards and Technology)
Raj K. Puri, M.D., Ph.D. (Food and Drug Administration)
Tal Salz, Ph.D. (Food and Drug Administration)
Barbara Sasu, PhD (Allogene Therapeutics)
Anthony Welch, PhD (National Cancer Institute)

Break

Cell Therapies: The FDA Perspective
Chair: Elad Sharon, MD, MPH (National Cancer Institute)

4:00pm – 4:30pm, Regulatory Perspective on the Preclinical Development of Cell-Based Immunotherapies, Alyssa Galaro, PhD (Food and Drug Administration)

4:30pm – 5:00pm, Identification and Assessment of Critical Quality Attributes for Cell-Based Therapies, Irina Tiper, PhD (Food and Drug Administration)

5:00pm – 5:30pm, FDA Clinical Assessment for First-In-Human Studies of Cell Therapy in Solid Tumors, Yuxia Jia, MD, PhD (Food and Drug Administration)

Panel Discussion
Alyssa Galaro, PhD (Food and Drug Administration)
Yuxia Jia, MD, PhD (Food and Drug Administration)
Irina Tiper, PhD (Food and Drug Administration)
Tal Salz, Ph.D. (Food and Drug Administration)
Elad Sharon, MD, MPH (National Cancer Institute)

Closing Remarks
Marc Ernstoff, MD (National Cancer Institute)